Base de dados : MEDLINE
Pesquisa : E01.370.225.124.100.115 [Categoria DeCS]
Referências encontradas : 11382 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1139 ir para página                         

  1 / 11382 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29505517
[Au] Autor:Abulimiti A; Husaiyin A; Sailai Y
[Ad] Endereço:Department of General Surgery, First Affiliated Hospital of Xinjiang Medical University, Urimqi, China.
[Ti] Título:Evaluation of HVHF for the treatment of severe acute pancreatitis accompanying MODS.
[So] Source:Medicine (Baltimore);97(1):e9417, 2018 Jan.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Systemic inflammatory response syndrome (SIRS) prevention is key to severe acute pancreatitis (SAP) treatment and the assessment of high-volume hemofiltration (HVHF) for treating SAP accompanying multiple organ dysfunction syndromes.In this prospective controlled study, 40 SAP patients were divided into 2 groups: control (n = 22, treated with fasting, decompression, and intravenous somatostatin) and HVHF (n = 18, HVHF administration in addition to the treatment in the control group) groups; and were assessed for serum and urine amylase, WBC, C-reactive protein (CRP), and hepatic and renal functions. Vital signs and abdominal symptoms were recorded, and complications and mortality were analyzed.APACHE II scores in the HVHF group were significantly lower than in the control group at 3 and 7 days (6.3 ±â€Š1.7 vs 9.2 ±â€Š2.1 and 3.3 ±â€Š0.8 vs 6.2 ±â€Š1.7, respectively). Compared with controls, serum, and urine amylase, WBC, CRP, and organ functions significantly improved after HVHF treatment. Meanwhile, mortality (16.7% vs 31.8%) and complication (11.1% vs 40.9%) rates were significantly reduced.The other clinical parameters were significantly ameliorated by HVHF. HVHF rapidly reduces abdominal symptoms and improves prognosis, reducing mortality in SAP patients; and is likely through systemic inflammatory response syndrome attenuation in the early disease stage.
[Mh] Termos MeSH primário: Hemofiltração/estatística & dados numéricos
Insuficiência de Múltiplos Órgãos/etiologia
Pancreatite/terapia
[Mh] Termos MeSH secundário: APACHE
Adulto
Idoso
Amilases/sangue
Amilases/urina
Nitrogênio da Ureia Sanguínea
Proteína C-Reativa/metabolismo
Feminino
Seres Humanos
Contagem de Leucócitos
Testes de Função Hepática
Masculino
Meia-Idade
Insuficiência de Múltiplos Órgãos/sangue
Insuficiência de Múltiplos Órgãos/urina
Pancreatite/sangue
Pancreatite/complicações
Pancreatite/urina
Estudos Prospectivos
[Pt] Tipo de publicação:CONTROLLED CLINICAL TRIAL; JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
9007-41-4 (C-Reactive Protein); EC 3.2.1.- (Amylases)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180306
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009417


  2 / 11382 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28458345
[Au] Autor:Xing Z; Pan W; Zhang J; Xu X; Zhang X; He X; Fan M
[Ad] Endereço:Department of Urology, The Third Affiliated Hospital of Soochow University.
[Ti] Título:Hydrogen Rich Water Attenuates Renal Injury and Fibrosis by Regulation Transforming Growth Factor-ß Induced Sirt1.
[So] Source:Biol Pharm Bull;40(5):610-615, 2017.
[Is] ISSN:1347-5215
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:The current research was designed to study the role of hydrogen in renal fibrosis and the renal epithelial to mesenchymal transition (EMT) induced by transforming growth factor-ß1 (TGF-ß1). Hydrogen rich water (HW) was used to treat animal and cell models. Unilateral ureteral obstruction (UUO) was performed on Balb/c mice to create a model of renal fibrosis. Human kidney proximal tubular epithelial cells (HK-2 cells) were treated with TGF-ß1 for 36 h to induce EMT. Serum creatinine (Scr) and blood urea nitrogen (BUN) were measured to test renal function, in addition, kidney histology and immunohistochemical staining of alpha-smooth muscle actin (α-SMA) positive cells was performed to examine the morphological changes. The treatment with UUO induced a robust fibrosis of renal interstitium, shrink of glomerulus and partial fracture of basement membrane. Renal function was also impaired in the experimental group with UUO, with an increase of Scr and BUN in serum. After that, Western-blot was performed to examine the expression of α-SMA, fibronectin, E-cadherin, Smad2 and Sirtuin-1 (Sirt1). The treatment with HW attenuated the development of fibrosis and deterioration of renal function in UUO model. In HK-2 cells, the pretreatment of HW abolished EMT induced by TGF-ß1. The down-regulation the expression of Sirt1 induced by TGF-ß1 which was dampened by the treatment with HW. Sirtinol, a Sirt1 inhibitor, reversed the effect of HW on EMT induced by TGF-ß1. HW can inhibit the development of fibrosis in kidney and prevents HK-2 cells from undergoing EMT which is mediated through Sirt1, a downstream molecule of TGF-ß1.
[Mh] Termos MeSH primário: Lesão Renal Aguda/tratamento farmacológico
Hidrogênio/uso terapêutico
Sirtuína 1/biossíntese
Fator de Crescimento Transformador beta/farmacologia
Água
[Mh] Termos MeSH secundário: Lesão Renal Aguda/patologia
Animais
Nitrogênio da Ureia Sanguínea
Linhagem Celular
Creatinina/sangue
Fibrose
Seres Humanos
Testes de Função Renal
Túbulos Renais Proximais/citologia
Túbulos Renais Proximais/efeitos dos fármacos
Túbulos Renais Proximais/patologia
Masculino
Camundongos
Camundongos Endogâmicos BALB C
Nefrite Intersticial/patologia
Sirtuína 1/genética
Obstrução Ureteral/complicações
Obstrução Ureteral/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Transforming Growth Factor beta); 059QF0KO0R (Water); 7YNJ3PO35Z (Hydrogen); AYI8EX34EU (Creatinine); EC 3.5.1.- (SIRT1 protein, human); EC 3.5.1.- (Sirt1 protein, mouse); EC 3.5.1.- (Sirtuin 1)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180212
[Lr] Data última revisão:
180212
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170502
[St] Status:MEDLINE
[do] DOI:10.1248/bpb.b16-00832


  3 / 11382 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29331653
[Au] Autor:Garud MS; Kulkarni YA
[Ad] Endereço:Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's NMIMS, V.L. Mehta Road, Vile Parle (W), Mumbai 400056, India.
[Ti] Título:Gallic acid attenuates type I diabetic nephropathy in rats.
[So] Source:Chem Biol Interact;282:69-76, 2018 Feb 25.
[Is] ISSN:1872-7786
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:Literature suggests that TGF-ß1 has a central role in the progression of diabetic nephropathy and its down regulation can improve the disease condition. Oxidative stress, generation of advanced glycation end products and activation of renin angiotensin system are the connecting links between hyperglycemia and TGF-ß1 over expression. Gallic acid is a phytochemical having wide range of biological activities. Gallic acid is reported to have antioxidant and advanced glycation inhibitory activity. It has also shown inhibitory effects on angiotensin converting enzyme. Gallic acid qualifies as a drug candidate to be tested in the diabetic nephropathy, one of the important complication of diabetes. Streptozotocin (55 mg/kg body weight, i.p.) induced diabetic nephropathy was used as an experimental model. Gallic acid was evaluated for its possible effect at the dose of 20 and 40 mg/kg body weight. Gallic acid treatment significantly lowered plasma levels of the creatinine and blood urea nitrogen and elevated the levels of the protein and albumin. Gallic acid also improved creatinine clearance. Determination of oxidative stress parameters showed that the oxidative stress in kidney tissues was reduced significantly in gallic acid treated animals. Results of the plasma, urine and oxidative stress parameters were also reflected in the histopathological evaluation showing improvement in kidney pathophysiology. ELISA assay for circulating TGF-ß1 evaluation and immunohistochemical study for determination of kidney expression of TGF-ß1 revealed that gallic acid significantly lowered both the circulating and tissue levels of TGF-ß1. Results support the hypothesis that gallic acid can be effectively used in the treatment of diabetic nephropathy.
[Mh] Termos MeSH primário: Diabetes Mellitus Tipo 1/complicações
Nefropatias Diabéticas/tratamento farmacológico
Nefropatias Diabéticas/etiologia
Ácido Gálico/farmacologia
[Mh] Termos MeSH secundário: Animais
Antioxidantes/farmacologia
Nitrogênio da Ureia Sanguínea
Creatinina/sangue
Diabetes Mellitus Experimental/induzido quimicamente
Diabetes Mellitus Experimental/complicações
Modelos Animais de Doenças
Rim/efeitos dos fármacos
Rim/metabolismo
Masculino
Estresse Oxidativo/efeitos dos fármacos
Ratos
Ratos Sprague-Dawley
Estreptozocina/farmacologia
Fator de Crescimento Transformador beta1/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antioxidants); 0 (Transforming Growth Factor beta1); 5W494URQ81 (Streptozocin); 632XD903SP (Gallic Acid); AYI8EX34EU (Creatinine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180209
[Lr] Data última revisão:
180209
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180115
[St] Status:MEDLINE


  4 / 11382 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29291386
[Au] Autor:Said E; Zaitone SA; Eldosoky M; Elsherbiny NM
[Ad] Endereço:Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.
[Ti] Título:Nifuroxazide, a STAT3 inhibitor, mitigates inflammatory burden and protects against diabetes-induced nephropathy in rats.
[So] Source:Chem Biol Interact;281:111-120, 2018 Feb 01.
[Is] ISSN:1872-7786
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:Diabetic nephropathy (DN) is a serious complication of diabetes mellitus. Moreover,it is amongst the most common causes of end-stage renal failure. Inflammation is a crucial player in both development and progression of DN. JAK2/STA3 is a pleotropic cascade reported to regulate diverse inflammatory events. Previous studies reported involvement of JAK2/STA3 signal transduction pathway in diabetes-associated renal injury. In the current study, the inhibitory effect of nifuroxazide (25 mg/kg/day, orally) against inflammatory condition associating diabetic kidney progression in rats was evaluated. The underlying hypothesis is mainly via the inhibitory effect of nifuroxazide on STAT3 signaling. Results revealed that nifuroxazide effectively inhibited STAT3 activation in diabetic male rats, improved glomerular filtration function, protected against diabetes-induced histopathological and ultramicroscopic structural alterations. Further, nifuroxazide treatment significantly reduced renal macrophage infiltration and fibrosis and decreased mRNA and protein levels of TNF-α and IL-18 in diabetic renal tissue. The current findings shed the light on nifuroxazide's efficacy as an alternative anti-inflammatory therapy to hinder the development and progression of DN in diabetic patients mainly via STAT3 inhibition.
[Mh] Termos MeSH primário: Anti-Inflamatórios/uso terapêutico
Diabetes Mellitus Experimental/complicações
Nefropatias Diabéticas/prevenção & controle
Hidroxibenzoatos/uso terapêutico
Nitrofuranos/uso terapêutico
Fator de Transcrição STAT3/antagonistas & inibidores
[Mh] Termos MeSH secundário: Animais
Anti-Inflamatórios/farmacologia
Nitrogênio da Ureia Sanguínea
Creatina/sangue
Diabetes Mellitus Experimental/induzido quimicamente
Diabetes Mellitus Experimental/patologia
Nefropatias Diabéticas/etiologia
Fibrose
Hidroxibenzoatos/farmacologia
Interleucina-18/genética
Interleucina-18/metabolismo
Janus Quinase 2/metabolismo
Rim/efeitos dos fármacos
Rim/metabolismo
Rim/patologia
Testes de Função Renal
Macrófagos/citologia
Macrófagos/imunologia
Masculino
Microscopia Eletrônica
Nitrofuranos/farmacologia
Ratos
Fator de Transcrição STAT3/metabolismo
Transdução de Sinais/efeitos dos fármacos
Estreptozocina/toxicidade
Fator de Necrose Tumoral alfa/genética
Fator de Necrose Tumoral alfa/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 0 (Hydroxybenzoates); 0 (Interleukin-18); 0 (Nitrofurans); 0 (STAT3 Transcription Factor); 0 (Tumor Necrosis Factor-alpha); 5W494URQ81 (Streptozocin); EC 2.7.10.2 (Janus Kinase 2); MU72812GK0 (Creatine); PM5LI0P38J (nifuroxazide)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180129
[Lr] Data última revisão:
180129
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180102
[St] Status:MEDLINE


  5 / 11382 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29274906
[Au] Autor:Yu S; Qi Y; Jiang J; Wang H; Zhou Q
[Ad] Endereço:Department of Ultrasound, the Second Hospital of Xi'an Jiao Tong University, Xi'an 710004, China.
[Ti] Título:APTR is a prognostic marker in cirrhotic patients with portal hypertension during TIPS procedure.
[So] Source:Gene;645:30-33, 2018 Mar 01.
[Is] ISSN:1879-0038
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Portal hypertension is a major cause of mortality and morbidity in cirrhotic patients. In this study, we aimed to analyze the clinical characteristics of Alu-mediated p21 transcriptional regulator (APTR) during transjugular intrahepatic portosystemic shunt (TIPS) procedure. Portal and hepatic venous blood was drawn from 84 patients with liver cirrhosis and portal hypertension before and after TIPS treatment. Then, we detected biochemical, hemodynamic parameters and APTR expression before and after TIPS treatment. Indeed, TIPS treatment could markedly ameliorate the serum blood urea nitrogen (BUN) level and portal vein hemodynamics in cirrhotic patients. We found that portal venous levels of APTR was significantly decreased after TIPS treatment and its aberrant expression levels were positively correlated with Model for End Stage Liver Disease (MELD), portal hepatic venous pressure gradient (PHPG) in patients. Higher APTR expression in portal vein was associated with poor prognosis. APTR level in portal vein was an independent predictors of mortality. Our data indicated that APTR may serve as a novel biomarker for cirrhotic patients with portal hypertension before and after receiving TIPS.
[Mh] Termos MeSH primário: Biomarcadores/sangue
Hipertensão Portal/cirurgia
Cirrose Hepática/complicações
RNA Longo não Codificante/sangue
[Mh] Termos MeSH secundário: Nitrogênio da Ureia Sanguínea
Feminino
Predisposição Genética para Doença
Seres Humanos
Hipertensão Portal/sangue
Hipertensão Portal/genética
Cirrose Hepática/sangue
Cirrose Hepática/genética
Cirrose Hepática/cirurgia
Masculino
Derivação Portossistêmica Transjugular Intra-Hepática
Prognóstico
Análise de Sobrevida
Resultado do Tratamento
Regulação para Cima
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (RNA, Long Noncoding); 0 (long non-coding RNA APTR, human)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180129
[Lr] Data última revisão:
180129
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171225
[St] Status:MEDLINE


  6 / 11382 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29261759
[Au] Autor:Chung HJ; Song YK; Hong SK; Hwang SH; Seo HS; Whang DH; Nam MH; Lee DH
[Ad] Endereço:Department of Laboratory Medicine, National Cancer Center, Goyang, South Korea.
[Ti] Título:Implementation of biological variation-based analytical performance specifications in the laboratory: Stringent evaluation of Improvacutor blood collection tubes.
[So] Source:PLoS One;12(12):e0189882, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Recently, because the quality of laboratory analyses has increased along with the need for quality improvement, several external quality control bodies have adapted performance specifications using the Desirable Biological Variation Database, termed "Ricos goals"; these criteria are more stringent than those presented in CLIA 88. In this study, we aimed to validate newly introduced serum separator tubes, Improvacutor, for routine clinical chemistry testing in accordance with Ricos goals and CLIA 88. Blood samples were collected from 100 volunteers into three types of serum vacuum tubes: Greiner Vacuette, Becton Dickinson (BD) Vacutainer, and Improve Improvacutor. The samples were subjected to 16 routine chemistry tests using a TBA-200fr NEO chemistry autoanalyzer. In the comparison analysis, all 16 test results were acceptable according to CLIA 88. However, in the comparison of Improve and BD tubes, creatinine showed 4.31% (+0.08 µmol/L) bias. This slightly exceeded the Desirable Specification for Inaccuracy Ricos limit of ±3.96%, but still satisfied the CLIS88 limit of ±26.52 µmol/L. The remaining 15 analytes performed acceptably according to the Desirable Specifications of Ricos. The correlation coefficient of 12 analytes was greater than 0.95 in Passing-Bablok regression analysis among the three tubes, but was lower for four analytes: calcium, sodium, potassium, and chloride. In the stability assay, only potassium tested in the Greiner tube revealed a larger positive bias (2.18%) than the Ricos Desirable Specification for Inaccuracy based on biologic variation (1.8%). The BD tube also showed a positive bias of 1.74%, whereas the new Improve tube showed the smallest positive bias of 1.17% in potassium level after 72 h storage. Thus, the results of this study demonstrate that recently introduced analytical performance specifications based on components of biological variation (Rico's goal) could be extended to criterion for performance evaluation and applied.
[Mh] Termos MeSH primário: Coleta de Amostras Sanguíneas/instrumentação
Laboratórios
[Mh] Termos MeSH secundário: Adulto
Idoso
Nitrogênio da Ureia Sanguínea
Cálcio/sangue
Creatinina/sangue
Feminino
Seres Humanos
Masculino
Meia-Idade
Temperatura Ambiente
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
AYI8EX34EU (Creatinine); SY7Q814VUP (Calcium)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180108
[Lr] Data última revisão:
180108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171221
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0189882


  7 / 11382 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28911818
[Au] Autor:Surhio MM; Wang Y; Fang S; Li J; Ye M
[Ad] Endereço:Microbial Resources and Application Laboratory, College of Food Science and Engineering, Hefei University of Technology, Hefei 230009, China.
[Ti] Título:Anti-fatigue activity of a Lachnum polysaccharide and its carboxymethylated derivative in mice.
[So] Source:Bioorg Med Chem Lett;27(20):4777-4780, 2017 10 15.
[Is] ISSN:1464-3405
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The present study was designed to evaluate the anti-fatigue activity of an exopolysaccharide LEP-1b and its carboxymethylated derivative CLEP-1b from a Lachnum sp. Carboxymethylation was confirmed through FT-IR and C NMR spectroscopies, which showed that the (-CH COOH) group was attached to an oxygen (O) atom of the hydroxyl group on (C-3) of LEP-1b. Each treatment group LEP-1b and CLEP-1b at doses (50, 100, 200mg/kg, respectively) ameliorated physical fatigue and extended exhaustive swimming time in mice. Results of the fatigue related biochemical markers showed that LEP-1b and CLEP-1b at doses (50, 100, 200mg/kg, respectively) increased the content of hepatic glycogen and decreased the level of serum urea nitrogen and lactic acid. Additionally, LEP-1b and CLEP-1b enhanced the antioxidant enzymes' activities and reduced the lipid peroxidation. Moreover, results revealed that CLEP-1b had higher anti-fatigue activity than LEP-1b at same doses but without statistical significance, especially CLEP-1b (200mg/kg) had strong anti-fatigue effects. Therefore, LEP-1b and CLEP-1b can potentially be exploited as a kind of healthcare compound to combat fatigue and to boost physical strength.
[Mh] Termos MeSH primário: Ascomicetos/química
Polissacarídeos/química
[Mh] Termos MeSH secundário: Animais
Ascomicetos/metabolismo
Nitrogênio da Ureia Sanguínea
Peso Corporal/efeitos dos fármacos
Fadiga/tratamento farmacológico
Peroxidação de Lipídeos/efeitos dos fármacos
Espectroscopia de Ressonância Magnética
Camundongos
Polissacarídeos/farmacologia
Polissacarídeos/uso terapêutico
Espectroscopia de Infravermelho com Transformada de Fourier
Natação
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Polysaccharides)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171125
[Lr] Data última revisão:
171125
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170916
[St] Status:MEDLINE


  8 / 11382 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28873450
[Au] Autor:Yokota T; Omachi K; Suico MA; Kojima H; Kamura M; Teramoto K; Kaseda S; Kuwazuru J; Shuto T; Kai H
[Ad] Endereço:Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto City, Kumamoto, Japan.
[Ti] Título:Bromide supplementation exacerbated the renal dysfunction, injury and fibrosis in a mouse model of Alport syndrome.
[So] Source:PLoS One;12(9):e0183959, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:A seminal study recently demonstrated that bromide (Br-) has a critical function in the assembly of type IV collagen in basement membrane (BM), and suggested that Br- supplementation has therapeutic potential for BM diseases. Because salts of bromide (KBr and NaBr) have been used as antiepileptic drugs for several decades, repositioning of Br- for BM diseases is probable. However, the effects of Br- on glomerular basement membrane (GBM) disease such as Alport syndrome (AS) and its impact on the kidney are still unknown. In this study, we administered daily for 16 weeks 75 mg/kg or 250 mg/kg (within clinical dosage) NaBr or NaCl (control) via drinking water to 6-week-old AS mice (mouse model of X-linked AS). Treatment with 75 mg/kg NaBr had no effect on AS progression. Surprisingly, compared with 250 mg/kg NaCl, 250 mg/kg NaBr exacerbated the progressive proteinuria and increased the serum creatinine and blood urea nitrogen in AS mice. Histological analysis revealed that glomerular injury, renal inflammation and fibrosis were exacerbated in mice treated with 250 mg/kg NaBr compared with NaCl. The expressions of renal injury markers (Lcn2, Lysozyme), matrix metalloproteinase (Mmp-12), pro-inflammatory cytokines (Il-6, Il-8, Tnf-α, Il-1ß) and pro-fibrotic genes (Tgf-ß, Col1a1, α-Sma) were also exacerbated by 250 mg/kg NaBr treatment. Notably, the exacerbating effects of Br- were not observed in wild-type mice. These findings suggest that Br- supplementation needs to be carefully evaluated for real positive health benefits and for the absence of adverse side effects especially in GBM diseases such as AS.
[Mh] Termos MeSH primário: Brometos/efeitos adversos
Nefropatias/metabolismo
Cirrose Hepática
Nefrite Hereditária/metabolismo
[Mh] Termos MeSH secundário: Animais
Nitrogênio da Ureia Sanguínea
Brometos/farmacologia
Creatinina/sangue
Modelos Animais de Doenças
Membrana Basal Glomerular/patologia
Rim/metabolismo
Masculino
Camundongos
Camundongos Endogâmicos C57BL
Nefrite/patologia
Nitrogênio/sangue
Compostos de Potássio/efeitos adversos
Compostos de Potássio/farmacologia
Proteinúria/metabolismo
Compostos de Sódio/efeitos adversos
Compostos de Sódio/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bromides); 0 (Potassium Compounds); 0 (Sodium Compounds); AYI8EX34EU (Creatinine); LC1V549NOM (sodium bromide); N762921K75 (Nitrogen); OSD78555ZM (potassium bromide)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171025
[Lr] Data última revisão:
171025
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170906
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0183959


  9 / 11382 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28872000
[Au] Autor:Beckham TH; Casey DL; LaQuaglia MP; Kushner BH; Modak S; Wolden SL
[Ad] Endereço:Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
[Ti] Título:Renal Function Outcomes of High-risk Neuroblastoma Patients Undergoing Radiation Therapy.
[So] Source:Int J Radiat Oncol Biol Phys;99(2):486-493, 2017 Oct 01.
[Is] ISSN:1879-355X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To analyze the renal function outcomes in patients undergoing radiation therapy for neuroblastoma. METHODS AND MATERIALS: The clinical metrics of renal function were analyzed in patients undergoing radiation therapy for high-risk neuroblastoma from 2000 to 2015. The blood urea nitrogen (BUN) and creatinine values before radiation therapy were compared with last available follow-up values and analyzed with the clinical circumstances, including follow-up length, age at primary irradiation, nephrectomy, and radiation technique. The creatinine clearance was estimated using the Shull method. RESULTS: With a median follow-up period of 3.5 years, none of the 266 patients studied developed a chronic renal insufficiency. For all patients, the creatinine level increased from 0.44 to 0.51 mg/dL and the BUN increased from 10.53 to 15.52 mg/dL. Three patients required antihypertensive medication. The patients who underwent intensity modulated radiation therapy did not experience increased creatinine levels during the follow-up period; however, they had a reduced median follow-up length compared with patients treated with anteroposterior/posteroanterior beams (4.7 vs 3.3 years). A longer follow-up length was associated with an increased creatinine level. The preradiation therapy creatinine level increased with patient age, similar to that of the last follow-up creatinine level, suggesting that the changes in creatinine could likely be explained by physiologic increases associated with aging rather than radiation-induced renal damage. The creatinine clearance did not decrease in any circumstance. CONCLUSIONS: The present cohort had excellent renal outcomes after radiation therapy for neuroblastoma. No patient developed chronic renal insufficiency, and the small increases in BUN and creatinine we observed correlated, as expected, with increases in patient age. The results of the present study revealed a possible advantage for intensity modulated radiation therapy in preserving renal function; however, the follow-up length is a recognized confounding variable. The kidneys are vital structures to consider when planning radiation therapy for neuroblastoma patients, and we have found encouraging evidence that modern techniques to spare them in the setting of multiple treatment-related insults have been successful.
[Mh] Termos MeSH primário: Nitrogênio da Ureia Sanguínea
Creatinina/sangue
Rim/efeitos da radiação
Neuroblastoma/radioterapia
Radioterapia de Intensidade Modulada
[Mh] Termos MeSH secundário: Adolescente
Criança
Pré-Escolar
Feminino
Seguimentos
Seres Humanos
Lactente
Rim/diagnóstico por imagem
Rim/fisiopatologia
Masculino
Nefrectomia/estatística & dados numéricos
Neuroblastoma/sangue
Neuroblastoma/cirurgia
Insuficiência Renal Crônica
Estudos Retrospectivos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
AYI8EX34EU (Creatinine)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171108
[Lr] Data última revisão:
171108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170906
[St] Status:MEDLINE


  10 / 11382 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
[PMID]:28832743
[Au] Autor:Caglayan M; Kosekahya P; Takmaz T; Altunoglu A; Ayan B; Atilgan CU; Uysal BS
[Ad] Endereço:Department of Ophthalmology, Ataturk Research and Training Hospital, Ankara, Turkey.
[Ti] Título:Effects of hemodialysis on corneal and anterior chamber morphometry and intraocular pressure in patients with end-stage renal disease.
[So] Source:Arq Bras Oftalmol;80(3):176-180, 2017 Jun.
[Is] ISSN:1678-2925
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To evaluate the effects of hemodialysis (HD) on corneal and anterior chamber morphometry, as well as intraocular pressure (IOP) in patients with end-stage renal disease. METHODS: Fifty right eyes were examined 30 minutes before and after HD. IOP was measured with a Goldmann applanation tonometer, and Ehlers' formula was used to calculate the corrected IOP values. The central corneal thickness (CCT), corneal volume (CV), keratometric values, anterior chamber depth (ACD), aqueous depth (AQD), anterior chamber volume (ACV), and anterior chamber angle (ACA) in the nasal and temporal quadrants were measured with a Sirius anterior segment analysis system. Blood urea nitrogen levels, body mass, and systolic and diastolic arterial pressure were also measured before and after HD. RESULTS: The mean age was 60.80 ± 13.38 (range: 35-80) years. The mean uncorrected and corrected IOP values decreased from 18.06 ± 3.91 and 18.31 ± 4.83 mmHg to 16.94 ± 3.87 and 16.95 ± 4.74 mmHg after HD, respectively (p=0.011 and p=0.003, respectively). The mean CCT decreased from 536.38 ± 24.73 to 533.18 ± 27.25 µm (p=0.002), and the mean CV decreased from 57.52 ± 3.15 to 55.68 ± 3.55 mm³ (p<0.001) after HD. There were no significant changes in ACD, AQD, ACV, ACA, or the keratometric values (p>0.05 for all values). There were no significant correlations between the ocular and systemic parameters (p>0.05 for all correlations). CONCLUSIONS: Uncorrected IOP, corrected IOP, CCT, and CV values decreased after HD, whereas the anterior chamber morphometry values remained similar between the measurements performed before and after HD.
[Mh] Termos MeSH primário: Câmara Anterior/patologia
Córnea/patologia
Pressão Intraocular/fisiologia
Falência Renal Crônica/fisiopatologia
Falência Renal Crônica/terapia
Diálise Renal/efeitos adversos
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Nitrogênio da Ureia Sanguínea
Paquimetria Corneana
Topografia da Córnea
Estudos Transversais
Feminino
Seres Humanos
Masculino
Meia-Idade
Valores de Referência
Estatísticas não Paramétricas
Fatores de Tempo
Tonometria Ocular
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170925
[Lr] Data última revisão:
170925
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170824
[St] Status:MEDLINE



página 1 de 1139 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde